This clinical trial is focused on studying a type of cancer called Relapsed/Refractory Lymphomas, which includes a condition known as Diffuse Large B-Cell Lymphoma (DLBCL). These are types of blood cancers that can return or do not respond to initial treatments. The study is evaluating a new treatment using a medication called Glofitamab, which is a special type of antibody designed to target and attack cancer cells. This medication is given as an infusion, meaning it is administered directly into the bloodstream through a vein. Another medication, Obinutuzumab, is also used in the study to help prepare the body for the main treatment.

The purpose of the study is to assess how well Glofitamab works in treating these lymphomas after patients have already received a type of therapy known as CAR T-cell therapy. This therapy involves modifying a patient’s own immune cells to better fight cancer. The study will involve a series of treatments over a period of time, with regular monitoring to see how the cancer responds to the medication. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

Participants in the study will receive the treatment through infusions and will be closely monitored by healthcare professionals. The study aims to understand the effectiveness of Glofitamab in improving survival rates and managing the disease. It will also look at how well patients tolerate the treatment and any changes in their quality of life. The study is designed to provide valuable information that could lead to better treatment options for people with these challenging types of lymphoma.